CGT Catapult announces vector production agreement with Adaptimmune

8th January 2018

The Cell and Gene Therapy (CGT) Catapult today announced it has signed an agreement with Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, for vector production at CGT Catapult’s UK based GMP manufacturing centre. The agreement will ensure vector supply production for Adaptimmune’s ongoing studies with all three SPEAR T-cell therapies, MAGE-A4, MAGE-A10 and AFP.

The manufacturing centre provides a Good Manufacturing Practice (GMP) environment in which companies can develop and operate their manufacturing processes and systems supported by the expertise and technologies of the Cell and Gene Therapy Catapult. Adaptimmune will be using one of six flexible large scale clean room modules within the GMP facility to produce its own novel vector and will be responsible for operation of its manufacturing process.

CGT Catapult is developing manufacturing systems including logistics, storage and supply chain capabilities to support Adaptimmune’s and other collaborators’ use of the facility.

This collaboration with Adaptimmune is a great example of a company using the capability we have developed to accelerate GMP manufacturing for global supply. It is the first announcement of a viral vector manufacturing agreement at the centre and represents part of our commitment to help UK companies overcome barriers to growth. Improving the capacity of UK companies and contract manufacturers to supply viral vectors is one of our key priorities, and we are delighted to work with Adaptimmune on this and to support the trials of their SPEAR T-cell therapies.

Keith Thompson, CEO, Cell and Gene Therapy Catapult





Funding Partners: